The
European Pharmacopeia intends to assess the following during 2018:
- 2.6.40. Monocyte-activation test for vaccines containing inherently pyrogenic components
- 5.26. Implementation of pharmacopoeial methods
- 5.27. Cross validation
- N-Boc-O-dimethoxytrityl-O’-nosyl-thymidine precursor for radiopharmaceutical preparations (3091)
- Erlotinib hydrochloride (3094)
- Eschscholzia herb (3088)
- (S)-3-(5-Formyl-4-methoxymethoxy-2-nitrophenyl)-2-(trityl-amino)-propionic acid tert-butyl ester precursor for radiopharmaceutical preparations (3093)
- Fulvestrant injection (3096)
- Helichrysi flos (3089)
- (2S)-O-(2‘-O’-Tosyloxyethyl)-N-trityl-tyrosine tert-butyl ester precursor for radiopharmaceutical preparations (3092)
- Vibriosis vaccine (inactivated) for sea bass (3090)
- Vincamine (1800)
Furthermore,
the following text is due to be revised:
Posted by Dr. Tim Sandle